Last checked at 27 Feb 2023 14:36
27 February 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Results of Annual General Meeting
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces that at the Company's Annual General Meeting held earlier today all resolutions were duly passed.
The Notice of Annual General Meeting containing the full text of all of the resolutions is available on the Company's website at www.oncimmune.com, the results of the proxy vote on each of the resolutions will also be made available on the Company's website shortly.
The Company will be holding a general meeting to, amongst other things, receive the Company's annual report for 15-month period ended 31 August 2022 ("FY22") and to approve the report on Directors' remuneration for FY22. A further announcement setting out details of this general meeting will be made in due course. The Company's FY22 annual report is also now available on the Company's website.
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
About Oncimmune
ImmunoINSIGHTS Service Business
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.
Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.
The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.
EarlyCDT Product Business
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.
Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.
For more information, visit www.oncimmune.com